Compare NGNE & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | ESRT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 834.5M |
| IPO Year | 2014 | 2012 |
| Metric | NGNE | ESRT |
|---|---|---|
| Price | $30.98 | $4.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $63.57 | $6.35 |
| AVG Volume (30 Days) | 234.1K | ★ 3.5M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $768,270,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | N/A | $1.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.05 |
| 52 Week Low | $15.93 | $3.93 |
| 52 Week High | $43.66 | $8.04 |
| Indicator | NGNE | ESRT |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | N/A |
| Support Level | $31.20 | N/A |
| Resistance Level | $33.99 | N/A |
| Average True Range (ATR) | 1.95 | 0.00 |
| MACD | -0.47 | 0.00 |
| Stochastic Oscillator | 20.29 | 0.00 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.